Regeneron Pharmaceuticals, Inc.
HealthcareNASDAQ:REGN · NASDAQ Global Select
+$0.66 today
Vol 0.70M · Avg 0.87M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
14.4%
avg 22.1%
ROIC
8.5%
avg 16.8%
ROA
11.1%
avg 15.9%
Analysis
ROE is currently the strongest return metric at 14.4% versus its period average of 22.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Leonard S. Schleifer | Co-Founder, President, Chief Executive Officer & Co-Chairman | $7.28M | — | 73 | $595,077.00 | 0.58% |
George D. Yancopoulos | Co-Founder, President, Chief Scientific Officer & Co-Chairman | $6.95M | — | 66 | $31,007.00 | 0.03% |
Joseph J. LaRosa | Executive Vice President, General Counsel & Secretary | $2.96M | — | 67 | $6,703.00 | <0.01% |
Daniel Van Plew | Executive Vice President and GM of Industrial Operations & Product Supply | $2.03M | — | 53 | $21,673.00 | 0.02% |
Andrew J. Murphy | Executive Vice President of Research & Co-Chief Scientific Officer | $1.73M | — | 68 | $47,833.00 | 0.05% |
Marion E. McCourt | Executive Vice President of Commercial | $1.50M | — | 66 | $14,349.00 | 0.01% |
Christopher R. Fenimore | Executive Vice President of Finance & Chief Financial Officer | $1.49M | — | 55 | $18,300.00 | 0.02% |
Ryan Steinberger | Executive VP, Chief Digital & Technology Officer | — | — | — | $17,523.00 | 0.02% |
Sally A. Paull | Executive Vice President of Human Resources | — | — | — | — | — |
Maya Bermingham | Senior Vice President of Public Policy & Government Affairs | — | — | — | — | — |
Melissa Lozner | Senior Vice President & Chief Compliance Officer | — | — | — | — | — |
Rajesh Ahuja | Senior Vice President of Quality Assurance & Operations | — | — | — | — | — |
Hanne Bak | Senior Vice President of Product, Analytical & Process Development | — | — | — | — | — |
John Lin | Senior VP of Antibody Technology, Oncology & Research | — | — | — | — | — |
Ned Braunstein | Executive Vice President of Regulatory Affairs and Global Patient Safety & Development Quality | — | — | — | — | — |
Ryan Crowe | Senior Vice President of Investor Relations & Strategic Analysis | — | — | — | $17,523.00 | 0.02% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
78
$9.47M
Net Sentiment
$9.47M
Net selling
Most Active
RYAN ARTHUR F
47 transactions
1–10 of 78
Analysis
Insiders reported 0 buys worth $0.00 and 78 sells worth $9.47M over the last 12 months. That adds up to net selling of $9.47M. RYAN ARTHUR F was the most active insider with 47 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -6.5% | +18.6% (15yr)6 analysts |
| Revenue | N/A | N/A | +43.9% | +11.7% (15yr)11 analysts |
| Net Income | N/A | N/A | -5.4% | +18.1% (15yr)11 analysts |
| EBIT | N/A | N/A | +39.6% | +13.8% (15yr)11 analysts |
Analysis
Recent growth has been strongest in Revenue at +43.9% over three years. Forward estimates point to EPS at +18.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Elevance Health Inc.
NYSE:ELV
$87.75B
Cigna Corporation
NYSE:CI
$78.83B
argenx SE
NASDAQ:ARGX
$55.29B
Cencora, Inc.
NYSE:COR
$54.80B
IDEXX Laboratories, Inc.
NASDAQ:IDXX
$44.24B
Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
$37.76B
Zoetis Inc.
NYSE:ZTS
$33.36B
United Therapeutics Corporation
NASDAQ:UTHR
$23.17B
Incyte Corporation
NASDAQ:INCY
$21.68B
Genmab A/S
NASDAQ:GMAB
$15.40B
Who manages REGN?
Regeneron Pharmaceuticals, Inc. (REGN) lists 16 active executives. The top listed executive is Christopher R. Fenimore, Executive Vice President of Finance & Chief Financial Officer.
Are REGN insiders buying or selling?
Recent insider activity shows net selling of $201.92M.
Explore More
Continue the stock analysis
Jump to another research area for this company.